Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 2407

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 8
Chunk 2407
---
 policy. Prior to 180 days after the date of the pricing
of our IPO, subject to early termination, the sale of any shares under such plans would be prohibited by the lock-up agreement
that the director or officer has entered into with the underwriters.

Item
11. Executive Compensation.

Our
named executive officers for 2024 were Mr. Francis Knuettel II, our Chief Executive Officer and President, Chief Financial Officer,
Treasurer and Secretary, and Dr. Eric Lang, our Chief Medical Officer. Mr. Knuettel was first appointed in June 2022, and Dr.
Lang was first appointed in May 2023.

Summary
Compensation Table

The
following table provides information regarding the compensation of our named executive officers during the years ended December
31, 2024 and 2023.

    Name and Principal Position 
    Year  
    Salary  
    Bonus  
    Option Awards  
    Non-Equity Incentive Plan Compensation  
    All Other Compensation  
    Total 

    Francis Knuettel II 
     2024  
    $424,923  
    $56,666  
    $361,833  
    $—  
    $—  
    $843,422 

    Chief Executive and Chief Financial Officer 
     2023  
    $107,500  
    $—  
    $199,510  
    $—  
    $—  
    $307,010 

    Eric Lang(1) 
     2024  
    $446,154  
    $—  
    $230,318  
    $—  
    $—  
    $676,472 

    Chief Medical Officer 
     2023  
    $166,767  
    $—  
    $120,735  
    $—  
    $—  
    $287,502 

    Christian Kopfli 
     2024  
    $—  
    $—  
    $—  
    $—  
    $—  
    $— 

    Former Chief Executive Officer, Former Chief Strategy Officer, and Former Vice Chairman (2) 
     2023  
    $11,280(3)  
    $—  
    $149,633  
    $—  
    $—  
    $